Linked Life Data

3864534

Source:http://linkedlifedata.com/resource/pubmed/id/3864534

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1-2
pubmed:dateCreated
1986-1-23
pubmed:abstractText
Since March, 1983, in vitro tests for the quantitative determination of the tumor-associated antigen Ca 19-9 (carbohydrate antigen 19-9) were performed in more than 300 patients with confirmed tumors. These tests had as a goal determination of the diagnostic value of this new potential tumor marker Ca 19-9 with regard to specificity and sensitivity of malignant growths in the gastrointestinal tract, breast, and lung. The applicability of Ca 19-9 RIA in posttherapeutic case control for early registration of recurrences and metastases was examined. First analyses of our patient collective confirmed the assumption that increased serum concentrations of Ca 19-9 are detectable in gastrointestinal tumors as well as in mammary and bronchial carcinoma. Thus Ca 19-9 is a nonspecific tumor-associated antigen that by itself does not allow an organ correlation of malignancies of the gastrointestinal tract, breast, and lung.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0361-090X
pubmed:author
pubmed:issnType
Print
pubmed:volume
8
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
101-9
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed:year
1985
pubmed:articleTitle
Clinical experience with the tumor marker Ca 19-9 in an unselected group of more than 300 tumor patients.
pubmed:publicationType
Journal Article